MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584915 | Name: Epristeride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2.

Chemical Structure

Epristeride
Epristeride
CAS#119169-78-7

Theoretical Analysis

MedKoo Cat#: 584915

Name: Epristeride

CAS#: 119169-78-7

Chemical Formula: C25H37NO3

Exact Mass: 399.2773

Molecular Weight: 399.58

Elemental Analysis: C, 75.15; H, 9.33; N, 3.51; O, 12.01

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Epristeride; ONO 9302; SK&F 105657; SKF 105657
IUPAC/Chemical Name
Androsta-3,5-diene-3-carboxylic acid, 17-(((1,1-dimethylethyl)amino)carbonyl)-, (17beta)-
InChi Key
VAPSMQAHNAZRKC-PQWRYPMOSA-N
InChi Code
InChI=1S/C25H37NO3/c1-23(2,3)26-21(27)20-9-8-18-17-7-6-16-14-15(22(28)29)10-12-24(16,4)19(17)11-13-25(18,20)5/h6,14,17-20H,7-13H2,1-5H3,(H,26,27)(H,28,29)/t17-,18-,19-,20+,24-,25-/m0/s1
SMILES Code
C[C@@]12[C@@H](C(NC(C)(C)C)=O)CC[C@@]1([H])[C@]3([H])CC=C4C=C(C(O)=O)CC[C@]4(C)[C@@]3([H])CC2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 399.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wu SF, Sun HZ, Tu ZH, Wu HY. Effect of epristeride on expression of TGF-beta receptor in rat prostatic epithelial cells in vitro. Acta Pharmacol Sin. 2001 Jun;22(6):516-20. PubMed PMID: 11747757. 2: Levy MA, Brandt M, Sheedy KM, Dinh JT, Holt DA, Garrison LM, Bergsma DJ, Metcalf BW. Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2. J Steroid Biochem Mol Biol. 1994 Feb;48(2-3):197-206. PubMed PMID: 8142295. 3: Qian LH, Wang XL, Tu ZH. Atrophy and apoptosis in ventral prostate of rats induced by 5alpha-reductase inhibitor, epristeride. Acta Pharmacol Sin. 2001 May;22(5):399-404. PubMed PMID: 11743885. 4: Sun ZY, Feng J, Qi XD, Wu HY, Zheng WJ, Tu ZH. Reversible long-term toxicity of epristeride in beagle dogs. Toxicol Appl Pharmacol. 1999 Jan 15;154(2):145-52. PubMed PMID: 9925798. 5: Wu SF, Sun HZ, Tu ZH, Wu HY. Inhibition of cultured rat prostatic epithelial cell growth by epristeride in vitro. Acta Pharmacol Sin. 2001 Mar;22(3):257-63. Erratum in: Acta Pharmacol Sin. 2001 May;22(5):449. PubMed PMID: 11742574. 6: Yao Z, Xu Y, Zhang M, Jiang S, Nicklaus MC, Liao C. Discovery of a novel hybrid from finasteride and epristeride as 5α-reductase inhibitor. Bioorg Med Chem Lett. 2011 Jan 1;21(1):475-8. doi: 10.1016/j.bmcl.2010.10.112. Epub 2010 Oct 28. PubMed PMID: 21094046. 7: Zhao XF, Yang Y, Wang W, Qiu Z, Zhang P, Wang B. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs. Chin Med J (Engl). 2013 Feb;126(4):711-5. PubMed PMID: 23422194. 8: Sun ZY, Wu HY, Wang MY, Tu ZH. The mechanism of epristeride against benign prostatic hyperplasia. Eur J Pharmacol. 1999 Apr 29;371(2-3):227-33. PubMed PMID: 10357260. 9: Wu JH, Sun ZY, Cao L. In vitro effects of epristeride on sperm in rats, dogs and man. Arch Androl. 2006 May-Jun;52(3):191-5. PubMed PMID: 16574601. 10: Robinson EJ, Collins AT, Robson CN, Neal DE. Effects of a new 5 alpha reductase inhibitor (epristeride) on human prostate cell cultures. Prostate. 1997 Sep 1;32(4):259-65. PubMed PMID: 9288184. 11: Akaza H, Tsukamoto S, Morita T, Yamauchi A, Onozawa M, Shimazui T, Ideyama Y, Shirai T. Promoting effects of antiandrogenic agents on rat ventral prostate carcinogenesis induced by 3,2'-dimethyl-4-aminobiphenyl (DMAB). Prostate Cancer Prostatic Dis. 2000 Aug;3(2):115-119. PubMed PMID: 12497109. 12: Higashiura K, Blaney B, Morgan E, Mathur RS, Halushka PV. Inhibition of testosterone 5 alpha-reductase: evidence for tissue-specific regulation of thromboxane A2 receptors. J Pharmacol Exp Ther. 1996 Dec;279(3):1386-91. PubMed PMID: 8968363. 13: Wu SF, Sun HZ, Qi XD, Tu ZH. Effect of epristeride on the expression of IGF-1 and TGF-beta receptors in androgen-induced castrated rat prostate. Exp Biol Med (Maywood). 2001 Nov;226(10):954-60. PubMed PMID: 11682703. 14: Boppana VK, Miller-Stein C, Rhodes GR. Normal-phase high-performance liquid chromatographic determination of epristeride, a prostatic steroid 5 alpha-reductase enzyme inhibitor, in human plasma. J Chromatogr. 1993 Feb 12;631(1-2):251-4. PubMed PMID: 8450017. 15: Ranjan M, Diffley P, Stephen G, Price D, Walton TJ, Newton RP. Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride. Life Sci. 2002 May 31;71(2):115-26. PubMed PMID: 12031682. 16: Hedge SS. Epristeride SmithKline Beecham. IDrugs. 1998 May;1(1):152-7. PubMed PMID: 18465521. 17: Gong A, Zhu X, Hu Y, Yu S. A fluorescence spectroscopic study of the interaction between epristeride and bovin serum albumine and its analytical application. Talanta. 2007 Oct 15;73(4):668-73. doi: 10.1016/j.talanta.2007.04.041. Epub 2007 May 5. PubMed PMID: 19073087. 18: Qian LH, Wang XL, Tu ZH. Inhibition of regrowth of prostatic glandular cells by epristeride. Acta Pharmacol Sin. 2001 Sep;22(9):847-50. PubMed PMID: 11749869. 19: Lao K, Sun J, Wang C, Lyu W, Zhou B, Zhao R, Xu Q, You Q, Xiang H. Design, synthesis and biological evaluation of novel androst-3,5-diene-3-carboxylic acid derivatives as inhibitors of 5α-reductase type 1 and 2. Steroids. 2017 Aug;124:29-34. doi: 10.1016/j.steroids.2017.05.011. Epub 2017 May 24. PubMed PMID: 28549802. 20: Gong AQ, Zhu XS. Determination of epristeride by its quenching effect on the fluorescence of L-tryptophan. J Pharm Anal. 2013 Dec;3(6):415-420. doi: 10.1016/j.jpha.2013.05.001. Epub 2013 May 18. PubMed PMID: 29403848; PubMed Central PMCID: PMC5761004.